Cargando…
Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1
The Golgi apparatus is increasingly recognized as a major hub for cellular signaling and is involved in numerous pathologies, including neurodegenerative diseases and cancer. The study of Golgi stress-induced signaling pathways relies on the selectivity of the available tool compounds of which curre...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Cell Biology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739293/ https://www.ncbi.nlm.nih.gov/pubmed/29074567 http://dx.doi.org/10.1091/mbc.E17-03-0176 |
_version_ | 1783287843467034624 |
---|---|
author | Gendarme, Mathieu Baumann, Jan Ignashkova, Tatiana I. Lindemann, Ralph K. Reiling, Jan H. |
author_facet | Gendarme, Mathieu Baumann, Jan Ignashkova, Tatiana I. Lindemann, Ralph K. Reiling, Jan H. |
author_sort | Gendarme, Mathieu |
collection | PubMed |
description | The Golgi apparatus is increasingly recognized as a major hub for cellular signaling and is involved in numerous pathologies, including neurodegenerative diseases and cancer. The study of Golgi stress-induced signaling pathways relies on the selectivity of the available tool compounds of which currently only a few are known. To discover novel Golgi-fragmenting agents, transcriptomic profiles of cells treated with brefeldin A, golgicide A, or monensin were generated and compared with a database of gene expression profiles from cells treated with other bioactive small molecules. In parallel, a phenotypic screen was performed for compounds that alter normal Golgi structure. Histone deacetylase (HDAC) inhibitors and DNA-damaging agents were identified as novel Golgi disruptors. Further analysis identified HDAC1/HDAC9 as well as BRD8 and DNA-PK as important regulators of Golgi breakdown mediated by HDAC inhibition. We provide evidence that combinatorial HDACi/(+)-JQ1 treatment spurs synergistic Golgi dispersal in several cancer cell lines, pinpointing a possible link between drug-induced toxicity and Golgi morphology alterations. |
format | Online Article Text |
id | pubmed-5739293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The American Society for Cell Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-57392932018-03-02 Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1 Gendarme, Mathieu Baumann, Jan Ignashkova, Tatiana I. Lindemann, Ralph K. Reiling, Jan H. Mol Biol Cell Articles The Golgi apparatus is increasingly recognized as a major hub for cellular signaling and is involved in numerous pathologies, including neurodegenerative diseases and cancer. The study of Golgi stress-induced signaling pathways relies on the selectivity of the available tool compounds of which currently only a few are known. To discover novel Golgi-fragmenting agents, transcriptomic profiles of cells treated with brefeldin A, golgicide A, or monensin were generated and compared with a database of gene expression profiles from cells treated with other bioactive small molecules. In parallel, a phenotypic screen was performed for compounds that alter normal Golgi structure. Histone deacetylase (HDAC) inhibitors and DNA-damaging agents were identified as novel Golgi disruptors. Further analysis identified HDAC1/HDAC9 as well as BRD8 and DNA-PK as important regulators of Golgi breakdown mediated by HDAC inhibition. We provide evidence that combinatorial HDACi/(+)-JQ1 treatment spurs synergistic Golgi dispersal in several cancer cell lines, pinpointing a possible link between drug-induced toxicity and Golgi morphology alterations. The American Society for Cell Biology 2017-12-15 /pmc/articles/PMC5739293/ /pubmed/29074567 http://dx.doi.org/10.1091/mbc.E17-03-0176 Text en © 2017 Gendarme et al. This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0). “ASCB®,” “The American Society for Cell Biology®,” and “Molecular Biology of the Cell®” are registered trademarks of The American Society for Cell Biology. |
spellingShingle | Articles Gendarme, Mathieu Baumann, Jan Ignashkova, Tatiana I. Lindemann, Ralph K. Reiling, Jan H. Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1 |
title | Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1 |
title_full | Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1 |
title_fullStr | Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1 |
title_full_unstemmed | Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1 |
title_short | Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1 |
title_sort | image-based drug screen identifies hdac inhibitors as novel golgi disruptors synergizing with jq1 |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739293/ https://www.ncbi.nlm.nih.gov/pubmed/29074567 http://dx.doi.org/10.1091/mbc.E17-03-0176 |
work_keys_str_mv | AT gendarmemathieu imagebaseddrugscreenidentifieshdacinhibitorsasnovelgolgidisruptorssynergizingwithjq1 AT baumannjan imagebaseddrugscreenidentifieshdacinhibitorsasnovelgolgidisruptorssynergizingwithjq1 AT ignashkovatatianai imagebaseddrugscreenidentifieshdacinhibitorsasnovelgolgidisruptorssynergizingwithjq1 AT lindemannralphk imagebaseddrugscreenidentifieshdacinhibitorsasnovelgolgidisruptorssynergizingwithjq1 AT reilingjanh imagebaseddrugscreenidentifieshdacinhibitorsasnovelgolgidisruptorssynergizingwithjq1 |